Goemkarponn Desk
PANAJI: A week after Cipla and Roche India announced that the first batch of the monoclonal antibody cocktail of Casirivimab and Imdevimab will be available in India, Horizon hospital in Goa administered the drug to a 49-year old patient on Monday.
“49 yrs , Dentist, with Asthma and allergy symptoms ( confirmed HDM allergy) , with 5 days symptoms. Successfully, Administered Antibody cocktail under close supervision at Horizon hospital and ICU today,” said Dr Salkar
Doctor Pravin Bhat is the first Doctor in Goa to administer the cocktail in Goa at the Horizon Hospital in Margão.
The monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight harmful pathogens and is to be administered for the treatment of mild to moderate Covid-19 in adults and paediatric patients (12 years or older), who are at high risk of developing severe disease.
The therapy is a cocktail of two drugs, Casirivimab and Imdevimab. The cocktail therapy claims to reduce hospitalisation and death in COVID-19 patients by 70 per cent. The drug is imported and marketed by the pharma companies Roche India and Cipla
